Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT03452683 Withdrawn - Heart Failure Clinical Trials

e-Diary in Heart Failure

Start date: April 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy and feasibility of using a smartphone application to monitor symptoms and weight in patients with advanced heart failure.

NCT ID: NCT03415906 Withdrawn - Heart Failure Clinical Trials

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure

ARNI-Sy
Start date: December 14, 2017
Phase: Phase 2
Study type: Interventional

The autonomic nervous system plays an important role in controlling the circulation. Increased sympathetic activity has detrimental effects in patients with heart failure. The purpose of this study is to test the hypothesis that combined angiotensin receptor + neprilysin inhibition results in lower sympathetic activity than angiotensin receptor inhibition alone.

NCT ID: NCT03340233 Withdrawn - Healthy Clinical Trials

Understanding the Mechanisms of Diastolic Dysfunction

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Heart failure is a clinical syndrome marked by breathlessness, even at low levels of exertion, general fatigue, and fluid retention and is estimated to affect 5.1 million people in the United States. Heart failure with preserved ejection fraction (HFpEF) means that the heart pumps enough blood to the body, but patients still have terrible symptoms. It is estimated to account for about 50% of all heart failure cases. Experts agree that impaired filling of the heart, perhaps due to "stiffness" of the heart muscle itself, critically underlies HFpEF. There is currently no clinical technique for measuring heart muscle (myocardial) stiffness; the very definition of "myocardial stiffness" remains poorly established. Consequently, the ability to study the mechanisms that underlie HFpEF is virtually non-existent, and limited treatment options will persist without significant advances. The objective of this project is to use an Equilibrium-Material-Stability (EMS) framework that couples patient-specific clinical MRI and heart pressure data in a computational model of the heart to diagnose changes in myocardial stiffness. The central hypothesis is that the new EMS framework for understanding the mechanisms of diastolic dysfunction in HFpEF will be more sensitive and outperform currently available approaches.

NCT ID: NCT03298009 Withdrawn - Heart Failure Clinical Trials

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

Canacardia
Start date: November 1, 2017
Phase: N/A
Study type: Interventional

It is a mechanistic proof-of-concept study to demonstrate how SGLT-2 inhibitors (Canagliflozin) may have a beneficial role on cardiac energetic efficiency. Patients with type 2 diabetes and with HF diagnosed for at least 3 months will be selected. The participants will be randomized to a double-blind, crossover 2-week placebo vs. Cana 100 mg once daily, an interventional trial with a one-month washout period in between. At the term of the two-week placebo and canagliflozin treatment periods (visits 2 and 4), each participant will undergo an identical postprandial metabolic study with positron emission tomography (PET) and stable isotopic tracer methods.

NCT ID: NCT03279861 Withdrawn - Hypertension Clinical Trials

Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD

Start date: November 2017
Phase: Phase 4
Study type: Interventional

This pilot, feasibility study evaluates the efficacy of sacubitril-valsartan (Entresto) versus usual anti-hypertensive medications in patients with left ventricular assist devices (LVAD). It also measures diurnal blood pressure variations in the context of continuous flow physiology.

NCT ID: NCT03227393 Withdrawn - Clinical trials for Heart Failure, Systolic

The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG

Start date: September 30, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate if yoga practice will reduce cardiac sympathetic activity and subsequently cardiac arrhythmias.

NCT ID: NCT03160625 Withdrawn - Clinical trials for Heart Failure With Preserved Ejection Fraction

Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF

RESPOND-HF
Start date: July 1, 2017
Phase: N/A
Study type: Interventional

RESPOND-HF is a prospective, multi-center, non-significant risk pilot study with cross-over design. The purpose of the study is to investigate if rate adaptive pacing has the potential to provide benefit to HF patients with preserved ejection fraction, referred to as HFpEF patients. Findings from this pilot study may be used to guide subsequent efforts to design and conduct a prospective, randomized, multi-center pivotal trial powered to show improvement in patient outcomes.

NCT ID: NCT03132441 Withdrawn - Heart Failure Clinical Trials

Cardiac Rehab for Advanced Heart Failure-LVAD Candidates

Start date: April 2017
Phase: N/A
Study type: Interventional

This study is a pilot study evaluating the feasibility and early efficacy of cardiac rehabilitation to improve frailty and symptoms in patients with advanced heart failure (NYHA class III-IV), who are being considered for LVAD therapy.

NCT ID: NCT03119623 Withdrawn - Clinical trials for Heart Failure With Reduced Ejection Fraction

Comparing ARNI With ACE Inhibitor on Endothelial Function

PARADOR
Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

PARADOR is multisite, randomized, double-blind, phase IV clinical trial to compare the effect of sacubitril/valsartan (Entresto™) to enalapril (Vasotec®) on blood vessel function in subjects with heart failure with reduced ejection fraction (HFREF).

NCT ID: NCT03091998 Withdrawn - Heart Failure Clinical Trials

Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support

CD-NP/LVAD
Start date: September 30, 2017
Phase: Phase 1
Study type: Interventional

The worldwide use of left ventricular assist devices (LVAD), which is mechanical device to improve hemodynamic function, has improved the outcomes of severe heart failure (HF) patients leading to the continued annual increase in the number of LVAD implantations. However LVAD support still results in major complications such as renal failure or gastrointestinal bleeding. The investigators hypothesize that such major complications may be due to endothelial dysfunction induced by the lack of pulsatility, which may be improved by an innovative designer natriuretic peptide, CD-NP. They have demonstrated its favorable actions in animal models as well as humans, and tested its safety in LVAD patients. They hypothesize that CD-NP will have renal and endothelial protective actions through its receptor GC-A and GC-B. Thus, the investigators will test their hypothesis with a highly translational approach to examine CD-NP's role in endothelial and renal protection. The aim is to determine safety and tolerability together with cGMP activating, neurohumoral modulating and renovascular protective properties of chronic subcutaneous delivery of CD-NP compared to placebo in stable LVAD patients for 3 days.